Biosimilars for Employer Consultants

The Access to Prescription Digital Therapeutics Act of 2023 will help ensure that the greatest number of patients possible are receiving innovative, modern care, which is especially vital for closing care gaps caused by specialist shortages or geographic obstacles. View the issue brief to learn more.

The Kidney Health Initiative convened a panel of experts in C3G to (1) assess the data supporting the use of the prespecified trial end points as measures of clinical benefit and (2) opine on efficacy findings they would consider compelling as treatment(s) of C3G in native kidneys. View the findings.

Panel of experts discussing targeted therapies to deliver improved patient outcomes in oncology.